课题基金 / 基金详情

New therapeutic approach for rheumatoid arthritis by targeting the intracellular molecule.

New therapeutic approach for rheumatoid arthritis by targeting the intracellular molecule.
通过靶向细胞内分子治疗类风湿性关节炎的新方法。
批准号:
14572167
负责人:
KAWAI Shinichi
金额:
$2.18万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2004

项目摘要

项目成果

KAWAI Shinichi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We found that some conventional nonsteroidal anti-inflammatory drugs(NSAIDs) such as indometacin and diclofenac induced apoptosis in rheumatoid synovial fibroblasts (J Pharmacol Exp Ther 2002;302:18). We also found that celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, exert pro-apoptotic effect on rheumatoid synovial fibroblasts (Arthritis Rheum 2002;46:3159) and colon cancer cell lines (FEBS Lett 2002;531:278) by COX-independent mechanisms. In addition, high concentration of aspirin and salicylate (J Pharm Pharmacol 2002;54:1675), and triptolide, an active compound identified in a traditional Chinese herb (BMC Pharmacol 2002;4:2), induce apoptosis in rheumatoid synovial cells. From these finding, we hypothesized that some intracellular molecules play an important role in inducing apoptosis by these anti-inflammatory agents. During the research procedure, we invented a novel potent pro-apoptotic agent derived from celecoxib. We are now trying to find the targeting molecule to i … More nduce apoptosis. Concerning arachidonic acid cascade, recent studies revealed that not only COX but also terminal enzymes such as prostaglandin E synthase(PGES) are important in the understanding of the pathogenesis of inflammation and mechanisms of action of NSAIDs. PGES is a recently identified terminal enzyme that acts downstream of COX and catalyzes the conversion of prostaglandin(PG) H2 to PGE2. At least three isozymes have been cloned so far, which are called membrane-associated PGES(mPGES)-1,mPGES-2,and cytosolic PGES. Induction of mPGES-1 in the component of articular tissues of patients with rheumatoid arthritis and osteoarthritis has been demonstrated in vitro by us (J Rheumatol 2002;29:1836 & Arthritis Res Ther 2004;6:R355). We then showed that PGE2 is an enhancer for interleukin-16-induced expression of mPGES-1 in rheumatoid synovial fibroblasts (Arthritis Rheum 2003;48:2819). These findings suggest that mPGES-1 may be a novel therapeutic target for arthritis. PGD synthase(PGDS) is an enzyme to produce an intrinsic pro-apoptotic PG (15-deoxy-Δ^<12,14>-PGJ2). We also found the anti-inflammatory effects of the retrovirally transfected PGDS-expressing fibroblasts in bleomycin-induced lung injury (Am J Respir Cell Mol Biol 2003;28:582) and monosodium urate monohydrate crystal-induced acute inflammation (Arthritis Rheum 2003;48:2931) in animal models. PGDS or 15-deoxy-Δ^<12,14>-PGJ2 will possibly be another target molecule for the novel therapy for rheumatoid arthritis and other rheumatic diseases. Less
期刊论文(114)
专著(0)
科研奖励(0)
会议论文
Current drug therapy for rheumatoid arthritis.
目前治疗类风湿性关节炎的药物治疗。
DOI: --
发表时间: 2003
期刊: J Orthop Sci 8(2)
影响因子: --
作者: [Kawai S]
通讯作者: Kawai S
Yamazaki R, Kawai S, et al.: "Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells"FEBS Lett. 531(2). 278-284 (2002)
Yamazaki R、Kawai S 等人:“选择性环氧合酶 2 抑制剂显示出抑制结肠腺癌细胞增殖和诱导细胞凋亡的不同能力”FEBS Lett。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: 10.1016/j.ijpharm.2003.10.027
发表时间: 2004-03
期刊: International journal of pharmaceutics
影响因子: 5.8
作者: [M. Takenaga;Y. Yamaguchi;A. Kitagawa;Y. Ogawa;S. Kawai;Y. Mizushima;R. Igarashi]
通讯作者: M. Takenaga;Y. Yamaguchi;A. Kitagawa;Y. Ogawa;S. Kawai;Y. Mizushima;R. Igarashi
Murakami Y, et al.: "Inhibition of monosodium urate monohydrate crystal-induced acute inflammation by retrovirally transfected prostaglandin D synthase."Arthritis Rheum. 48(10). 2931-2941 (2003)
Murakami Y 等人:“通过逆转录病毒转染的前列腺素 D 合酶抑制一水尿酸钠晶体诱导的急性炎症。”关节炎大黄。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
31
    Pharmacogenetic study of methotrexate in patients with rheumatoid arthritis.
    • 批准号:
      26461477
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.16万
    • 财政年份:
      2014
    • 负责人:
      KAWAI Shinichi
    • 依托单位:
    Adipokine network in systemic autoimmune diseases
    • 批准号:
      23591449
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.33万
    • 财政年份:
      2011
    • 负责人:
      KAWAI Shinichi
    • 依托单位:
    Interfirm division of labor and network in oversea business--Comparative analysis of Japanese and Chinese enterprises.
    • 批准号:
      20402033
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.65万
    • 财政年份:
      2008
    • 负责人:
      KAWAI Shinichi
    • 依托单位:
    Clinical Significance of Adipocytokines in Rheumatoid Arthritis
    • 批准号:
      20591177
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2008
    • 负责人:
      KAWAI Shinichi
    • 依托单位:
    国内基金
    海外基金
    视交叉上核PPARgamma在高脂饮食诱导的节律紊乱中的作用
    • 批准号:
      81971234
    • 项目类别:
      面上项目
    • 资助金额:
      55.0万元
    • 批准年份:
      2019
    • 负责人:
      王雪敏
    • 依托单位:
    高卵泡刺激素经PPARgamma途径在绝经女性胰岛素抵抗发生中的作用机制研究
    • 批准号:
      81701368
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2017
    • 负责人:
      宋阳
    • 依托单位:
    谷氨酸对神经元PPARgamma的调节作用及机制研究
    • 批准号:
      81571201
    • 项目类别:
      面上项目
    • 资助金额:
      57.0万元
    • 批准年份:
      2015
    • 负责人:
      孙莉
    • 依托单位:
    过氧化亚硝基阴离子ONOO-对核因子PPARgamma硝化修饰及其在脑缺血损伤中的作用
    • 批准号:
      81401023
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      22.0万元
    • 批准年份:
      2014
    • 负责人:
      徐艳炜
    • 依托单位: